Lecanemab in Early Alzheimer’s Disease

In a phase 3 trial, participants with early Alzheimer’s disease who received the monoclonal antibody lecanemab had less decline on measures of cognition and function at 18 months than those who received placebo.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-01, Vol.388 (1), p.9-21
Hauptverfasser:	van Dyck, Christopher H., Swanson, Chad J., Aisen, Paul, Bateman, Randall J., Chen, Christopher, Gee, Michelle, Kanekiyo, Michio, Li, David, Reyderman, Larisa, Cohen, Sharon, Froelich, Lutz, Katayama, Sadao, Sabbagh, Marwan, Vellas, Bruno, Watson, David, Dhadda, Shobha, Irizarry, Michael, Kramer, Lynn D., Iwatsubo, Takeshi
Format:	Artikel
Sprache:	eng
Schlagworte:	Activities of Daily Living Aging Alzheimer Disease Alzheimer Disease - diagnostic imaging Alzheimer Disease - drug therapy Alzheimer's disease Amyloid beta-Peptides - cerebrospinal fluid Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Biomarkers Body weight Cerebrospinal fluid Clinical trials Cognition - drug effects Cognitive ability Coronaviruses COVID-19 Dementia Dementia disorders Double-Blind Method Drug dosages Edema FDA approval Geriatrics Humans Immunoglobulin G Intravenous administration Life Sciences Magnetic resonance imaging Memory Monoclonal antibodies Neurodegenerative diseases Neuroimaging Neurology Neurosurgery Nootropic Agents - adverse effects Nootropic Agents - pharmacology Nootropic Agents - therapeutic use Placebos Positron emission tomography Psychiatry Psychiatry General Technical communication
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a phase 3 trial, participants with early Alzheimer’s disease who received the monoclonal antibody lecanemab had less decline on measures of cognition and function at 18 months than those who received placebo.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2212948